Chris Gibson
Co-Founder and Board Chair, Recursion Pharmaceuticals · USA
Chris Gibson is the CEO of Recursion Pharmaceuticals (RXRX). Gibson is based in USA. Gibson has held the role since 2013.
PhD graduate of the University of Utah who co-founded Recursion Pharmaceuticals in 2013. He developed the technology underlying Recursion's AI drug discovery platform during his graduate work and led the company as CEO from its founding through 2025, growing it from an early-stage startup to a publicly listed clinical-stage biotech company.
Recent developments
AI summary of recent coverageRecent coverage has focused on Chris Gibson's transition away from leading Recursion Pharmaceuticals after more than a decade as CEO, culminating in a departure from the board in mid-2026 while remaining in an advisory capacity. Following the leadership change, Gibson joined venture capital firm Dimension Capital, where coverage indicates he applied experience gained from running the AI-focused drug development company. The headlines reflect attention to both Gibson's tenure building Recursion's AI platform for pharmaceutical development and the company's subsequent shift toward demonstrating clinical efficacy under new leadership.
Summarized from the headlines below; see each source for the full story.
Our coverage
On CEOInsider
No feature yet. When we publish a feature, interview or cover story on Chris Gibson, it will appear here — and tie into the news timeline.
Chris Gibson: FAQ
- Who is Chris Gibson?
- Chris Gibson is the Co-Founder and Board Chair of Recursion Pharmaceuticals, based in USA.
- What company does Chris Gibson lead?
- Chris Gibson is CEO of Recursion Pharmaceuticals, a role held since 2013.